Business Description
Eagle Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US2697961082
Share Class Description:
EGRX: Ordinary SharesDescription
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | 1.27 | |||||
| Interest Coverage | 6.32 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 1.88 | |||||
| Beneish M-Score | -1.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.5 | |||||
| 3-Year EBITDA Growth Rate | 43.8 | |||||
| 3-Year EPS without NRI Growth Rate | 39.3 | |||||
| 3-Year FCF Growth Rate | -0.3 | |||||
| 3-Year Book Growth Rate | 10.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.3 | |||||
| 9-Day RSI | 43.06 | |||||
| 14-Day RSI | 42.94 | |||||
| 6-1 Month Momentum % | -63.95 | |||||
| 12-1 Month Momentum % | -81.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.16 | |||||
| Quick Ratio | 1.67 | |||||
| Cash Ratio | 0.18 | |||||
| Days Inventory | 240.58 | |||||
| Days Sales Outstanding | 137.58 | |||||
| Days Payable | 80.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.5 | |||||
| Shareholder Yield % | -40.59 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.84 | |||||
| Operating Margin % | 15.92 | |||||
| Net Margin % | 4.64 | |||||
| FCF Margin % | -3.64 | |||||
| ROE % | 4.99 | |||||
| ROA % | 3 | |||||
| ROIC % | 5.79 | |||||
| ROC (Joel Greenblatt) % | 49.77 | |||||
| ROCE % | 12.15 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 4.66 | |||||
| PE Ratio without NRI | 1.94 | |||||
| Shiller PE Ratio | 2.67 | |||||
| PS Ratio | 0.23 | |||||
| PB Ratio | 0.22 | |||||
| Price-to-Tangible-Book | 0.56 | |||||
| EV-to-EBIT | 3.23 | |||||
| EV-to-EBITDA | 2.05 | |||||
| EV-to-Revenue | 0.45 | |||||
| EV-to-FCF | -12.28 | |||||
| Price-to-Projected-FCF | 0.08 | |||||
| Price-to-Graham-Number | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 1.61 | |||||
| Earnings Yield (Greenblatt) % | 30.96 | |||||
| FCF Yield % | -17.08 | |||||
| Forward Rate of Return (Yacktman) % | 62.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EGRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eagle Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 257.551 | ||
| EPS (TTM) ($) | 0.91 | ||
| Beta | 0.59 | ||
| Volatility % | 62.19 | ||
| 14-Day RSI | 42.94 | ||
| 14-Day ATR ($) | 0.410815 | ||
| 20-Day SMA ($) | 4.798 | ||
| 12-1 Month Momentum % | -81.77 | ||
| 52-Week Range ($) | 4.1 - 30.4 | ||
| Shares Outstanding (Mil) | 12.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eagle Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eagle Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eagle Pharmaceuticals Inc Frequently Asked Questions
What is Eagle Pharmaceuticals Inc(EGRX)'s stock price today?
The current price of EGRX is $4.24. The 52 week high of EGRX is $30.40 and 52 week low is $4.10.
When is next earnings date of Eagle Pharmaceuticals Inc(EGRX)?
The next earnings date of Eagle Pharmaceuticals Inc(EGRX) is 2024-04-29 Est..
Does Eagle Pharmaceuticals Inc(EGRX) pay dividends? If so, how much?
Eagle Pharmaceuticals Inc(EGRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers